ArticleBlood and lymphatic cancer : targets and therapy2026
Long-Term Results of Busulfan Plus High-Dose Idarubicin as a Conditioning Regimen to Autologous Stem Cell Transplantation Following Cytarabine Consolidation in Young Patients with Favorable or Intermediate-Risk Acute Myeloid Leukemia.
Article in Blood and lymphatic cancer : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the long-term efficacy and safety of high-dose idarubicin plus busulfan (I-Bu) conditioning followed by autologous stem cell transplantation (ASCT) compared to intermediate- to high-dose cytarabine (Ara-C) consolidation in young acute myeloid leukemia (AML) patients with favorable- or intermediate-risk in first complete remission (CR Methods: We retrospectively analyzed clinical data from 59 young AML patients (aged ≤ 65 years) with favorable- or intermediate-risk disease who received the I-Bu conditioning regimen followed by ASCT between December 2004 and December 2021 (ASCT group). Clinical outcomes were compared with 57 favorable- and intermediate-risk AML patients treated with intermediate- to high-dose Ara-C consolidation chemotherapy alone (chemotherapy group). Overall survival (OS) and disease-free survival (DFS) were evaluated, and univariate and multivariate analyses were performed to identify prognostic factors associated with OS. Results: A total of 116 patients were included with a median follow-up of 79.5 months. Median OS was not reached in either group. The ASCT group achieved a significantly higher 2-year OS rate (84.5% vs 59.7%, Conclusion: The I-Bu conditioning regimen followed by ASCT provides durable survival benefits and a favorable safety profile for young, favorable-risk AML patients in CR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.